Advertisement
JNJ vs MRK
Which Stock Would AI Choose? Johnson & Johnson (JNJ) vs. Merck & Co. (MRK) Stock Comparison
Key Takeaways
- JNJ recently proposed a $5.5 billion talc settlement and completed acquisitions including Firefly Bio and Sail Biomedicines, supporting its oncology and MedTech expansion.
- MRK received FDA approval for Lipfendra, an oral PCSK9 inhibitor, and advanced HIV prevention licensing plans across 129 countries ahead of its Q2 earnings.
- JNJ affirmed 2026 revenue guidance near $100.8–101.4 billion while adjusting EPS outlook after recent deals, trading near the upper end of its 52-week range.
- MRK stock has shown resilience with multiple analyst price target increases, reflecting pipeline momentum in oncology and cardiovascular areas.
- JNJ offers broader revenue diversification across pharmaceuticals and MedTech, while MRK maintains higher operating margins from its focused pharma model.
- Relative performance in recent weeks highlights JNJ's stability amid litigation resolution versus MRK's catalyst-driven volatility.
Introduction
Johnson & Johnson (JNJ) and Merck & Co. (MRK) represent two leading healthcare companies with substantial market capitalizations and established pharmaceutical portfolios. This comparison examines their recent stock behavior, business drivers, and market positioning to assist investors and traders evaluating relative value within the healthcare sector. Portfolio managers seeking dividend stability, growth-oriented traders monitoring pipeline catalysts, and those analyzing sector rotation may find the analysis relevant. The focus remains on observable factors such as revenue trends, recent corporate actions, and analyst sentiment shifts over recent weeks.
JNJ Overview and Recent Performance
Johnson & Johnson operates across innovative medicine and MedTech segments, generating revenue from pharmaceuticals, medical devices, and consumer health products. In recent market activity, the stock traded near the upper portion of its 52-week range following resolution of talc-related litigation through a proposed $5.5 billion settlement. Acquisitions of Firefly Bio and Sail Biomedicines expanded its oncology capabilities, though these moves prompted a modest reduction in full-year 2026 EPS guidance while revenue targets were affirmed near $100.8–101.4 billion. FDA marketing authorization for the OTTAVA robotic surgery platform provided additional positive momentum. Overall sentiment benefited from litigation clarity and pipeline progress amid broader healthcare sector stability.
MRK Overview and Recent Performance
Merck & Co. focuses primarily on pharmaceuticals, with key products in oncology, vaccines, and infectious diseases. Recent weeks featured FDA approval of Lipfendra, its first oral PCSK9 cholesterol-lowering pill, alongside plans for early licensing of an HIV prevention treatment across 129 countries. Positive data from Keytruda trials and analyst price target increases supported the stock, which has maintained positions above its 200-day moving average. Upcoming second-quarter earnings are anticipated with expectations for continued pipeline advancement. Market sentiment reflects optimism around new product launches and cardiovascular developments, tempered by the ongoing transition away from legacy products.
Trending AI Robots
Tickeron maintains a curated section highlighting Trending AI Robots, where only the highest-performing and most market-appropriate AI trading bots are featured from a broader library of hundreds of bots that trade thousands of tickers. These bots encompass varied trading styles, strategies, timeframes, and performance statistics tailored to different market conditions and asset sets. Available metrics often include ranges for win rates, profit factors, and drawdown controls that allow users to evaluate suitability. The platform provides transparent data on each bot’s historical results and ticker focus. For further details on current trending options, visit the Trending AI Robots page.
Head-to-Head Comparison
Johnson & Johnson maintains a diversified business model spanning pharmaceuticals and MedTech, offering greater revenue stability compared to Merck’s more concentrated pharma focus and higher operating margins. Growth drivers differ, with JNJ benefiting from MedTech expansion and oncology acquisitions, while MRK advances through targeted approvals in cardiovascular and HIV areas. Recent momentum favors JNJ on litigation resolution and guidance affirmation, whereas MRK shows strength in analyst revisions and new product catalysts. Risk factors include acquisition-related EPS dilution for JNJ and legacy product headwinds for MRK. Sector exposure remains similar within healthcare, though market sentiment has leaned toward JNJ for near-term visibility and MRK for pipeline optionality.
Tickeron AI Verdict
Based on observable factors including revenue diversification, trend consistency in recent weeks, and catalyst visibility, Tickeron’s AI framework would likely express a probabilistic preference for JNJ over MRK in the current environment. JNJ demonstrates stronger near-term momentum through litigation resolution and multi-segment growth, supporting more balanced positioning. MRK offers compelling long-term pipeline potential but faces greater near-term variability from product transitions. This assessment reflects relative data patterns and does not constitute investment advice or a definitive prediction.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JNJ is a Buy and MRK is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
JNJ’s FA Score shows that 4 FA rating(s) are green whileMRK’s FA Score has 3 green FA rating(s).
- JNJ’s FA Score: 4 green, 1 red.
- MRK’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
JNJ’s TA Score shows that 3 TA indicator(s) are bullish while MRK’s TA Score has 4 bullish TA indicator(s).
- JNJ’s TA Score: 3 bullish, 5 bearish.
- MRK’s TA Score: 4 bullish, 4 bearish.
Price Growth
JNJ (@Pharmaceuticals: Major) experienced а -2.68% price change this week, while MRK (@Pharmaceuticals: Major) price change was -0.66% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -1.41%. For the same industry, the average monthly price growth was -2.13%, and the average quarterly price growth was +3.17%.
Reported Earning Dates
JNJ is expected to report earnings on Oct 20, 2026.
MRK is expected to report earnings on Aug 04, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-1.41% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| JNJ | MRK | JNJ / MRK | |
| Capitalization | 618B | 322B | 192% |
| EBITDA | 34B | 19.4B | 175% |
| Gain YTD | 25.245 | 25.506 | 99% |
| P/E Ratio | 29.74 | 36.68 | 81% |
| Revenue | 97.9B | 65.8B | 149% |
| Total Cash | 20.8B | N/A | - |
| Total Debt | 49B | 49.1B | 100% |
JNJ | MRK | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 33 | 10 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 13 Undervalued | 19 Undervalued | |
PROFIT vs RISK RATING 1..100 | 6 | 42 | |
SMR RATING 1..100 | 38 | 47 | |
PRICE GROWTH RATING 1..100 | 17 | 11 | |
P/E GROWTH RATING 1..100 | 13 | 5 | |
SEASONALITY SCORE 1..100 | 65 | 45 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
JNJ's Valuation (13) in the Pharmaceuticals Major industry is in the same range as MRK (19). This means that JNJ’s stock grew similarly to MRK’s over the last 12 months.
JNJ's Profit vs Risk Rating (6) in the Pharmaceuticals Major industry is somewhat better than the same rating for MRK (42). This means that JNJ’s stock grew somewhat faster than MRK’s over the last 12 months.
JNJ's SMR Rating (38) in the Pharmaceuticals Major industry is in the same range as MRK (47). This means that JNJ’s stock grew similarly to MRK’s over the last 12 months.
MRK's Price Growth Rating (11) in the Pharmaceuticals Major industry is in the same range as JNJ (17). This means that MRK’s stock grew similarly to JNJ’s over the last 12 months.
MRK's P/E Growth Rating (5) in the Pharmaceuticals Major industry is in the same range as JNJ (13). This means that MRK’s stock grew similarly to JNJ’s over the last 12 months.
| JNJ | MRK | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 36% | 3 days ago 51% |
| Stochastic ODDS (%) | 3 days ago 47% | 3 days ago 65% |
| Momentum ODDS (%) | 3 days ago 41% | 3 days ago 57% |
| MACD ODDS (%) | 3 days ago 48% | 3 days ago 52% |
| TrendWeek ODDS (%) | 3 days ago 42% | 3 days ago 49% |
| TrendMonth ODDS (%) | 3 days ago 49% | 3 days ago 55% |
| Advances ODDS (%) | 6 days ago 44% | 10 days ago 55% |
| Declines ODDS (%) | 4 days ago 42% | 4 days ago 51% |
| BollingerBands ODDS (%) | 5 days ago 40% | 6 days ago 45% |
| Aroon ODDS (%) | 3 days ago 49% | 3 days ago 65% |
Advertisement
MRK and
Correlation & Price change
A.I.dvisor indicates that over the last year, MRK has been loosely correlated with NVS. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if MRK jumps, then NVS could also see price increases.